Abstract: The present invention relates to a novel crystalline cefdinir potassium dihydrate, to a process for its preparation and to a method of preparing pure cefdinir via the crystalline salt.

Abstract: The present invention relates to processes for the preparation of zolpidem of Formula V as shown in the accompanying drawings or pharmaceutically acceptable salts thereof from N,N-dimethyl-3-(4-methyl)benzoyl propionamide of Formula II. The process includes (a) reacting N,N-dimethyl-3-(4-methyl)benzoyl propionamide of Formula II with bromine to get the bromo amide of Formula III; (b) condensing the bromo amide of Formula III with 2-amino-5-methylpyridine of Formula IV to get the zolpidem base of Formula V; and (c) converting zolpidem base of Formula V to its hemitartarate salt of Formula VII.

Abstract: The present invention relates to a cost effective and industrially advantageous process for the preparation of tolterodine and pharmaceutically acceptable salts thereof.

Abstract: The invention relates to an amorphous form of the salts of the (−) enantiomer or (S)-enantiomer of omeprazole, i.e., esomeprazole. The invention also relates to processes for preparing amorphous esomeprazole salts and pharmaceutical compositions that include the amorphous esomeprazole salts.

Abstract: The present invention relates to a cost effective and industrially advantageous process for the preparation of tolterodine and pharmaceutically acceptable salts thereof.

Abstract: The present invention relates to an improved and industrially advantageous process for the preparation of N-(5-methylnicotinoyl)-4-hydroxypiperidine of Formula I, as shown in the accompanied drawings. This compound is a key intermediate for the synthesis of rupatadine, a potent dual antagonist of histamine and platelet-activating factor (PAF).

Abstract: The present invention relates to a cost effective and industrially useful process for the preparation of substantially pure acitretin. More specifically, the present invention relates to the preparation of acitretin of high purity and yield.

Abstract: The present invention relates to an improved and industrially advantageous process for the preparation of N, N-dimethyl-3-(4-methyl)benzoyl propionamide, which compound is a key intermediate for the synthesis of zolpidem hemitartrate, a non-benzodiazepine hypnotic agent.

Abstract: The present invention relates to an improved and industrially advantageous process for the preparation of N-(5-methylnicotinoyl)-4-hydroxypiperidine of Formula I, as shown in the accompanied drawings. This compound is a key intermediate for the synthesis of rupatadine, a potent dual antagonist of histamine and platelet-activating factor (PAF).

Abstract: A method for adaptively scheduling maintenance of a sensor (14) infers the need for maintenance of that sensor on the basis of an error signal indicative of a difference between a measurement signal generated by that sensor and an independently obtained reference signal that is correlated with the measurement signal (16). Although the reference signal is not identical to the measurement signal, the correlation between these two signals assures that when the sensor is functioning, the two signal will track each other over time. The method includes the step of generating this error signal and then monitoring that error signal to detect a triggering event indicative of a mismatch between the reference signal and the measurement signal. This mismatch is indicative of a probability that there exists a malfunction in the sensor. The value of this probability depends on the choice of the triggering event.